Guangwei Du

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6351412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dynamics of Nigral Iron Accumulation in Parkinson's Disease: From Diagnosis to Late Stage. Movement Disorders, 2022, 37, 1654-1662.	3.9	18
2	Folded concave penalized learning of high-dimensional MRI data in Parkinson's disease. Journal of Neuroscience Methods, 2021, 357, 109157.	2.5	1
3	Low plasma serotonin linked to higher nigral iron in Parkinson's disease. Scientific Reports, 2021, 11, 24384.	3.3	7
4	Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease. Movement Disorders, 2020, 35, 2028-2037.	3.9	64
5	Clinical Progression of Parkinson's Disease: Insights from the NINDS Common Data Elements. Journal of Parkinson's Disease, 2020, 10, 1075-1085.	2.8	13
6	Magnetic resonance <scp>T</scp> 1w/ <scp>T</scp> 2w ratio: A parsimonious marker for <scp>P</scp> arkinson disease. Annals of Neurology, 2019, 85, 96-104.	5.3	33
7	Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients. Movement Disorders, 2018, 33, 1423-1431.	3.9	75
8	Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes. Movement Disorders, 2018, 33, 1432-1439.	3.9	43
9	Combined Diffusion Tensor Imaging and Apparent Transverse Relaxation Rate Differentiate Parkinson Disease and Atypical Parkinsonism. American Journal of Neuroradiology, 2017, 38, 966-972.	2.4	32
10	Quantitative susceptibility mapping of the midbrain in Parkinson's disease. Movement Disorders, 2016, 31, 317-324.	3.9	133
11	Stage-dependent loss of cortical gyrification as Parkinson disease "unfolds― Neurology, 2016, 86, 1143-1151.	1.1	36
12	Multi-atlas segmentation of subcortical brain structures via the AutoSeg software pipeline. Frontiers in Neuroinformatics, 2014, 8, 7.	2.5	98
13	Higher iron in the red nucleus marks Parkinson's dyskinesia. Neurobiology of Aging, 2013, 34, 1497-1503.	3.1	76
14	Imaging nigral pathology and clinical progression in Parkinson's disease. Movement Disorders, 2012, 27, 1636-1643.	3.9	107
15	Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease. Movement Disorders, 2011, 26, 1627-1632.	3.9	163